Xarelto Lawsuits Progress, As Federal Court Prepares to Move Forward with Bellwether Trial Selections, Bernstein Liebhard LLP Reports

New York, New York   January 11, 2016   Business News
(PRLEAP.COM) January 11, 2016 - Thousands of Xarelto lawsuits (http://www.rxinjuryhelp.com/xarelto/lawsuit/) involving the medication's alleged bleeding side effects continue to move forward in the multidistrict litigation now underway in U.S. District Court, Eastern District of Louisiana. According to an Order dated December 17th, the Court has begun the process of selecting 40 Xarelto cases for the proceeding's bellwether trial pool. The Order stipulates that plaintiffs and the defense are to select 10 cases each for the pool by January 11th, five of which are to have originated in the Eastern District of Louisiana, one from Mississippi, one from Texas and three cases from other states. Though they are not required to do so, the Order asks that the parties "endeavor" to choose at least one case from each of six injury categories identified by the Court:

  • Individuals who suffered a gastrointestinal bleed while using Xarelto to prevent stroke,
  • Individuals who suffered a brain bleed/hemorrhagic stroke while using Xarelto to prevent stroke.
  • Individuals who experienced rectal bleeding while using Xarelto to prevent stroke,
  • Individuals who suffered a gastrointestinal bleed while using Xarelto to treat pulmonary embolism or deep vein thrombosis.
  • Individuals who suffered a brain bleed/hemorrhagic stroke while using Xarelto to treat pulmonary embolism or deep vein thrombosis.
  • Individuals who experienced rectal bleeding while using Xarelto to treat pulmonary embolism or deep vein thrombosis.

  • By January 15th, the Court will randomly select 20 additional Xarelto lawsuits. These selections will include 10 from Louisiana, two from Mississippi and one each from eight other states selected by the parties. (In Re: Xarelto Products Liability Litigation, No. 2592)

    "Our Firm is representing a number of Xarelto plaintiffs in this proceeding, and we are pleased that the Court is moving forward with its bellwether trial plan. The outcome of these cases could provide valuable insight into how juries might decide similar Xarelto lawsuits," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.

    Xarelto Bleeding Litigation
    Xarelto is a new generation blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in 2011. It is currently indicated for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. Xarelto's label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.

    At least 2,400 Xarelto lawsuits are now pending in the Eastern District of Louisiana, where all federal cases involving its alleged bleeding side effects have been consolidated for the purposes of coordinated pretrial proceedings. Plaintiffs charge that the drug's manufacturers concealed Xarelto's serious risks, and wrongly promoted it as an improvement over warfarin, a blood thinner that has been on the market for decades. Among other things, the complaints note that internal bleeding associated with warfarin can be stopped via the administration of vitamin K. By contrast, there is currently no approved antidote to reverse Xarelto bleeding.

    The Court has indicated that it will convene four bellwether trials beginning in February 2017. The first two Xarelto trials will get underway in the Eastern District of Louisiana on February 6, 2017 and March 13, 2017. The third and fourth will take place in yet-to-be determined Districts in Mississippi and Texas on April 24, 2017 and May 30, 2017.

    Individuals who allegedly experienced uncontrollable Xarelto bleeding or other complications that could be related to its use may be eligible to join the growing litigation involving the blood thinner. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.

    About Bernstein Liebhard LLP
    Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

    Bernstein Liebhard LLP
    10 East 40th Street
    New York, New York 10016

    ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact Information:
    Sandy A. Liebhard, Esq.
    Bernstein Liebhard LLP
    info (at)consumerinjurylawyers(dot)com
    Contact Information
    Sandy Liebhard
    RX Injury Help
    Contact Us